Welcome to our dedicated page for Keen Vision Acquisition SEC filings (Ticker: kvacw), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to follow KVACW’s fast-moving SPAC disclosures? Between redemption tables, biotech risk factors, and sponsor warrant clauses, Keen Vision Acquisition Corp. filings can easily top 300 pages. Our platform eliminates that complexity so you can focus on the numbers that move the stock.
Stock Titan’s AI reads every document the instant it hits EDGAR, then serves clear answers to questions investors actually ask, like “KVACW insider trading Form 4 transactions” or “Where is KVACW’s quarterly earnings report 10-Q filing?” Whether you need the latest 8-K detailing its Medera gene-therapy merger, a proxy statement on executive compensation, or a concise view of trust-account interest in the annual report, our real-time engine translates legal jargon into plain language.
- Instant alerts on KVACW Form 4 insider transactions real-time, including sponsor warrant sales
- AI-powered summaries of every 10-K and 10-Q—no scrolling required to see cash held in trust
- Side-by-side comparison of each amended proxy so you can spot new dilution terms fast
- Contextual explanations of 8-K material events, from LOI announcements to closing conditions
Mizuho Financial Group reported beneficial ownership of 973,800 common shares of Keen Vision Acquisition Corporation, representing 9.0% of the class. The filing shows sole voting and sole dispositive power over all 973,800 shares, and identifies the reporting person as a parent holding company organized in Japan.
The filing is a Schedule 13G/A disclosure and includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control. The schedule also notes that Mizuho Securities USA LLC directly holds the securities and related Mizuho entities may be deemed indirect beneficial owners.
Keen Vision Acquisition Corporation (KVAC) held $73,062,664 in its Trust Account as of June 30, 2025, up from $70,373,065 at year-end, producing dividend income that contributed to net income of $1,126,226 for the six months ended June 30, 2025 versus $5,040,728 in the prior year period. The company entered into a Merger Agreement to combine with Medera Inc., valuing 100% of Medera at $622,560,000 with an implied Acquirer share value of $10.00. Management has repeatedly deposited extension payments into the Trust Account (multiple $200,000 deposits and a $144,670 deposit on July 23, 2025) to extend the business combination deadline to August 27, 2025. The company reported a working capital deficit of $2,772,485 and minimal cash at bank ($1,317), and discloses substantial doubt about its ability to continue as a going concern if a business combination is not completed by the deadline.
Keen Vision Acquisition Corporation: W. R. Berkley Corporation and its subsidiary Berkley Insurance Company each report beneficial ownership of 1,046,168 ordinary shares, representing 9.7% of the outstanding class based on the issuer's reported 10,820,727 ordinary shares outstanding. The holders disclose shared voting power and shared dispositive power over 1,046,168 shares and report zero sole voting and zero sole dispositive power.
The filers certify the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The disclosure is made on Schedule 13G/A by W. R. Berkley Corporation and Berkley Insurance Company.
Keen Vision Acquisition Corporation ("KVAC") has filed a PRE 14A preliminary proxy statement to convene an Extraordinary General Meeting on 23 July 2025 in Hong Kong. Shareholders will vote on three key proposals that directly affect the special-purpose acquisition company’s (SPAC) life span and capital structure.
Proposal 1 – Trust Amendment: KVAC seeks authority to extend the deadline for commencing liquidation of its $72.6 million trust account up to six additional one-month periods, shifting the current cut-off from 27 July 2025 to 27 January 2026. Each monthly extension would require a deposit of $0.03 per remaining public share ("Extension Payment") instead of the existing flat $200,000 monthly fee. The change reduces the sponsor’s cash outlay when public share redemptions shrink the float and provides incremental optionality rather than a single long extension.
Proposal 2 – Charter Amendment: To give full legal effect to Proposal 1, shareholders must adopt a Third Amended & Restated Memorandum and Articles that formally sets the new outside date at 27 January 2026.
Proposal 3 – Adjournment: Allows the chair to adjourn the meeting if there are insufficient votes to pass Proposals 1 or 2, facilitating additional proxy solicitation.
Public shareholders may elect to redeem their ordinary shares for a pro-rata share of the trust regardless of how they vote. Redemption requests must reach Continental Stock Transfer & Trust at least two business days before the meeting via share certificate delivery or DWAC. If Proposals 1 & 2 fail and no business combination closes by the current deadline, the company will liquidate and redeem 100 % of Public Shares within ten business days.
The record date is 26 June 2025. The Trust Amendment requires approval by at least 50 % of all outstanding ordinary shares; the Charter Amendment and Adjournment proposals need a majority of shares present and voting. The Board unanimously recommends voting "FOR" all proposals, asserting that the lower, per-share extension cost aligns shareholder and sponsor interests while preserving the option to consummate a value-enhancing business combination.
FAQ
What is the current stock price of Keen Vision Acquisition (kvacw)?
